Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJ0QLB)

Drug Name	PMID27410995-Compound-Figure3k Drug Info
Cross-matching ID	TTD Drug ID DMJ0QLB

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Ribosomal protein S6 kinase (S6K)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LYS-6KAKT1	DMLXGAI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
LY2780301	DM93AJW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
XL418	DME0F5W	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
LY-2584702	DML8M3B	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ribosomal protein S6 kinase (S6K)	TT7M3PI	NOUNIPROTAC	Activator	[1]

------------------------------------------------------------------------------------

References

1	Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
2	DOI: 10.1016/S1359-6349(10)71767-5
3	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9.
4	Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer
5	A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.Eur J Cancer.2014 Mar;50(5):876-84.